Table I.
Patient characteristics.
| Characteristic | Value |
|---|---|
| Total patients | 65 |
| Median age, years (range) | 72 (57–81) |
| Median initial PSA, ng/ml (range) | 13.1 (4.1–57.8) |
| Initial PSA, n (%) | |
| <10 ng/ml | 24 (36.9) |
| 10–20 ng/ml | 23 (35.4) |
| >20 ng/ml | 18 (27.7) |
| Gleason score, n (%) | |
| 6 | 7 (10.8) |
| 7 | 29 (44.6) |
| 8–10 | 29 (44.6) |
| Clinical T stage, n (%) | |
| T1c | 17 (26.2) |
| T2a | 14 (21.5) |
| T2b | 9 (13.8) |
| T2c | 3 (4.6) |
| T3a | 18 (27.7) |
| T3b | 3 (4.6) |
| T4 | 1 (1.5) |
| Risk groupa, n (%) | |
| Low | 2 (3.1) |
| Intermediate | 21 (32.3) |
| High | 38 (58.5) |
| Very high | 4 (6.2) |
| Neoadjuvant ADT, n (%) | |
| Not administered | 15 (23.1) |
| Administered | 50 (76.9) |
| Follow-up, months (range) | 30.1 (12.0–42.7) |
a
Risk group was categorized using the national comprehensive cancer network risk group classification. PSA, prostate-specific antigen; ADT, androgen deprivation therapy.